Kyung Dong Pharm: Q1 2026 Operating Profit +57.6%, Net Debt Ratio Improves to 3.85%
-
Consolidated Q1 2026 sales KRW 47.8B (+4.4% YoY), operating profit KRW 2.4B (+57.6%), net profit KRW 4.7B (+190.6%)
-
Standalone: sales KRW 47.6B, operating profit KRW 2.8B, net profit KRW 4.2B, EPS KRW 152
-
Declared year-end cash dividend of KRW 300 per share (total KRW 8.3B)
-
Net debt ratio improved to 3.85% (from 5.28% at FY2025), borrowings reduced to KRW 18.4B
-
Non-operating income boosted by financial asset valuation gains
KOSDAQ Filing Information
-
Filing: Quarterly Report (2026.03)
-
Company: KyungdongPharm (011040)
-
Submission: KyungdongPharm
-
Receipt: 05-14-2026